drugset / Trial / NCT00313976
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of the study is to evaluate if the higher dose can give greater efficacy without negative impact on the adverse event profile for patients with early secondary progressive Multiple Sclerosis (SPMS).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Interferon beta-1b | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | Interferon beta-1b | Protein / enzyme biologic | 500 ug | Subcutaneous |